This report highlights the challenges of managing patients with neuromuscular comorbidities undergoing chemotherapy and the use of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors as adjuvant therapy in breast cancer treatment. This evidence concerns the gene CDK4 and breast carcinoma.